A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin
about
Nanocarriers for delivery of platinum anticancer drugs.Emerging role of liposomal drug carrier systems in cancer chemotherapy.Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle.Impact of nanotechnology in cancer: emphasis on nanochemopreventionNew-generation platinum drugs in the treatment of cisplatin-resistant cancers.Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin.The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.Liposomes, a promising strategy for clinical application of platinum derivatives.Application of liposomal technologies for delivery of platinum analogs in oncology.Platinum-based drugs: past, present and future.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.Speciation of Phenanthriplatin and Its Analogs in the Core of Tobacco Mosaic Virus.
P2860
Q34338695-9971DAF4-8B2C-40DF-A232-1AC2D8D32332Q35119246-D91DB1D1-60CC-4036-B9D9-2CCD22977176Q35551143-68325C52-F525-4FFD-977D-F55BF7533FE4Q35750624-95B8B27B-23AE-45A8-B3D7-2AB5E2CF7C4EQ36210926-2B703DBF-1260-4D98-BFF8-64279856A16BQ37551919-15AF561A-014C-4AFE-9D3B-94F4904BFD68Q37815479-9502490D-4AE7-429A-9D04-8D70AEC93854Q37983912-F38622A4-D17B-432F-A28A-82AFB7DF81B4Q38087423-C67E33EA-9CA7-4522-872D-409E0D0B55BCQ38136184-A602B8C7-4D81-441B-BBDA-DA605922AC51Q38737115-C0C88F59-7972-4884-B1FF-8EE22AEFE75FQ38961012-9C6B64C4-CFC4-44D8-A94B-E763C1577305Q39377012-899CE950-C889-4416-A509-8D3A930F613DQ52649156-F010503E-B7E7-437D-B03B-06F4FF37EDBB
P2860
A phase I study in paediatric patients to evaluate the safety and pharmacokinetics of SPI-77, a liposome encapsulated formulation of cisplatin
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A phase I study in paediatric ...... lated formulation of cisplatin
@ast
A phase I study in paediatric ...... lated formulation of cisplatin
@en
A phase I study in paediatric ...... lated formulation of cisplatin
@nl
type
label
A phase I study in paediatric ...... lated formulation of cisplatin
@ast
A phase I study in paediatric ...... lated formulation of cisplatin
@en
A phase I study in paediatric ...... lated formulation of cisplatin
@nl
prefLabel
A phase I study in paediatric ...... lated formulation of cisplatin
@ast
A phase I study in paediatric ...... lated formulation of cisplatin
@en
A phase I study in paediatric ...... lated formulation of cisplatin
@nl
P2093
P2860
P356
P1476
A phase I study in paediatric ...... lated formulation of cisplatin
@en
P2093
Griffin MJ
Pearson AD
P2860
P2888
P304
P356
10.1054/BJOC.2001.1723
P407
P577
2001-04-01T00:00:00Z
P5875
P6179
1013766234